Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

An important clinical trial announcement is good news for this healthcare stock. The post Bell Potter is tipping this exciting ASX healthcare stock to rise 80% appeared first on The Motley Fool ...

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...